Cansativa Awarded 4-Year German Medical Cannabis Flower Distribution Contract

Cansativa is awarded the distribution of cannabis flowers from German cultivation on behalf of the Cannabis Agency

The Cannabis Agency of the Federal Institute for Drugs and Medical Devices (BfArM) commissions Cansativa to provide logistics and general services for the wholesale trade of all German cannabis cultivation. The order for the distribution of cannabis for medical purposes totalling 10.4 tons was granted for four years.

Cansativa GmbH (“Cansativa”) announced today that they were the only company to be awarded the contract by the Federal Institute for Drugs and Medical Devices (BfArM) to roll out distribution, logistics and general services for the wholesale of cannabis flowers from German cultivation. On behalf of the cannabis agency, Cansativa will distribute the cannabis flowers from German cultivation to pharmacies and be among other things responsible for storage, commissioning and outgoing logistics.

We are proud that our tender proposal and our expertise in the field of medical cannabis have convinced the BfArM and that we have been awarded this contract. It is an important step for patients in Germany who will thus have access to new products. We are honoured to be able to contribute to a sustainable supply with our services on behalf of the Cannabis Agency.

Jakob Sons, co-founder and general counsel of Cansativa

By winning the contract, Cansativa will coordinate the central distribution of cannabis flowers grown by Aurora, Aphria and Demecan in Germany on behalf of the Cannabis Agency. The contract with the BfArM will run for four years with a total volume of up to 10.4 tons.

Cansativa has been importing and distributing medical cannabis to a large number of German pharmacies for over two years. The German market is the largest and fastest growing market for medical cannabis in Europe. With a comprehensive multi-brand portfolio of products from leading international manufacturers such as Aurora, Bedrocan, Tweed and Tilray, Cansativa has developed into an independent “one-stop shop” to become a specialised wholesaler and a single-point-of-contact for medical cannabis in the German market.

“We are pleased to be able to use the experience we have gained from our previous business activities for the BfArM now as well. With our comprehensive product portfolio, we will act nationally and internationally as an independent wholesale partner and aim to further professionalise the market. Our goal is to strengthen Cansativa as a central platform for the purchase and distribution of medical cannabis,” explains Benedikt Sons, co-founder and CEO of Cansativa.

Cansativa is considered a pioneer in the industry and works continuously to improve the supply of medical cannabis.

About Cansativa GmbH

Founded in 2017, Cansativa is a GMP-certified pharmaceutical company and holds a GDP pharmaceutical wholesale license to trade in controlled substances. From its headquarter in Moerfelden-Walldorf, Germany, Cansativa and its subsidiaries work to professionalize the medical cannabis market, eliminate stigmatization and to permanently reduce prices for patients. As an owner-managed company, our growth target is linked to a long-term vision – we want to set industry-wide benchmarks.

Since the very beginning, Cansativa has operated its own distribution and fulfillment center, and as one of its industry’s “first movers”, it has become one of the largest independent manufacturers, importers, and distributors of medical cannabis in Germany. From its location in Mörfelden-Walldorf, the company supplies pharmacies and pharmaceutical wholesalers throughout Germany. Cansativa is uniquely positioned as „one-stop shop“ with a comprehensive multi-brand portfolio in the German market and secures the supply of medical cannabis pharmaceuticals. Cansativa is the only company that has been contracted by the Federal Institute for Drugs and Medical Devices (BfArM) to distribute and to provide logistics and wholesale services for the entire German cannabis production for the next four years. Through our top-notch partnership network with well-known suppliers, pharmacists can order a broad range of products such as API, pharmaceuticals and medical devices via our Cansativa platform.

Original press release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter